Amoxicillin, cefotaxime, ceftriaxone, gentamicin, doxycycline, and ofloxacin were active in vitro, like the reference drug streptomycin, against the virulent strain Yersinia pestis 6/69M. The comparative efficacies of these drugs in vivo were evaluated in a standardized and reproducible mouse model of systemic infection. Each antibiotic was injected intravenously once, at 24 h postinfection, and then repeatedly during 48 h. In vivo results were measured by counting the viable bacteria recovered from the whole spleens of mice sacrificed at selected times. All the drugs were manifestly successful; ceftriaxone, ofloxacine, and the reference drug were the most effective. Therefore, gentamicin and doxycycline could be used, depending on the clinical forms of the Y. pestis infection. Further investigations on beta-lactams, especially those used in the present study, could be carried out to confirm or not confirm their activities against Y. pestis. Ofloxacin appeared to be as active and to perform as rapidly as streptomycin in the treatment of murine Y. pestis infection, which is in agreement with the previous successes obtained with the use of fluoroquinolones in the treatment of murine infections caused by other pathogenic yersiniae.
effects.
In the face of this dilemma, it seemed to us that it would be useful to evaluate the in vivo comparative efficacies of newer antibiotics like fluoroquinolones and extended-spectrum cephalosporins against Y. pestis, as we did previously against * Corresponding author.
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the two other pathogenic yersiniae (19, 26, 28) ; we also tested another aminoglycoside (gentamicin), an aminopenicillin (amoxicillin), and another cycline (doxycycline). In the study described here, we used a reproducible systemic Y pestis infection in mice caused by a virulent isolate from a human.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The strain used to infect mice was Y pestis 6/69M, which was isolated in Madagascar from a patient suffering from bubonic plague. This strain belongs to the subgroup Y pestis var. orientalis (glycerol negative, nitrous acid positive) (1) and harbors the three usual plasmids (21) and the associated virulence irp2 gene (8) . Its 50% lethal dose by intravenous (i.v.) injection in mice is less than 10 CFU.
A collection of 18 Y pestis strains was selected at the French National Yersinia Center, Institut Pasteur, Paris, France. Thirteen strains belonging to the subgroup Y pestis var. orientalis were isolated in India, Java, Madagascar, Senegal, Turkey, the United States, and Vietnam. Two In vitro susceptibility tests. The MICs of the seven antibiotics were determined for the 19 strains of Y pestis by the dilution method in Mueller-Hinton (MH) agar with a multipoint inoculator (Denley Instruments Ltd., Billinghurst, England) as described previously (16, 27 The MBCs of the seven antibiotics were determined for Y pestis 6/69M by the macrodilution method in MH broth as described previously (16) . The initial inoculum, which was prepared as described above, was approximately 106 CFU. The MBC was defined as the lowest concentration of drug that permitted at least a 99.9% (103-fold) reduction in the number of CFU. The cultures were enumerated after 6 and 24 h at 280C.
E. coli ATCC 25922 and S. aureus ATCC 25923 were used as quality controls with each antibiotic in each experiment.
Pharmacokinetic assays in infected mice. The doses of antibiotics administered to the mice were those used in previously reported experimental infections in mice (4, 10, 12, 13, 29, 32) . They were selected to achieve about the same peak levels (or, more exactly, early concentrations) in the sera of mice as are achieved in the sera of humans (see Table 2 ). The individual antibiotics were administered to the mice at 24 h postinfection. Groups of 12 mice each were used for each antibiotic. At selected time points (at least three) after antibiotic administration, three mice were anesthetized by exposure to chloroform, and blood was obtained from the inferior vena cava. The samples were centrifuged at 10,000 rpm for 5 min (Sorvall RCSC, rotor SS34), and then the serum specimens were removed and frozen at -20°C for 5 days at the most. The serum specimens were assayed by the microbiological technique (diffusion in agar) (9 Table 2 ). In all the experiments, untreated control animals received sterile physiological saline.
Assessment of infection and therapy. At 8 and 24 h postinfection, the control mice (n = 5) were killed to check the exponential growth of Y pestis and to count the number of bacteria in the spleen at the time of the initiation of therapy. Thereafter, five animals from each group of mice, treated or untreated, were sacrificed at 8 and 24 h after the initiation of therapy for the first series of experiments and at 8, 24, and 56 h after the initiation of therapy for the second series of experiments. The spleens of the mice were aseptically removed and were homogenized in 1.5 ml of sterile physiological saline. The whole homogenate of each spleen removed at 8 h postinfection was plated onto TSH agar and was incubated for 48 h at 28°C to determine the number of viable bacteria. At the next time points, serial 10-fold dilutions of the homogenates were made and 150-,ul samples were plated in the same manner. Therefore, except for the 8-h postinfection time point, the detection limit for bacterial counts in spleen homogenates was 10 CFU. Finally, for each antibiotic, five mice were observed until day 15 in order to estimate the mortality rate.
Pathology. Histologic examinations of the spleens of infected mice obtained at 24, 32, and 48 h postinfection were done. At each time point three mice were killed by cervical dislocation, and the spleens were placed in a solution of Boin de Hollande. The sections stained by the Mann-Dominici method were examined.
Detection of antibiotic-resistant bacteria. To determine whether the bacteria recovered from the spleens at 48 h in the first experiment might have been resistant mutants selected by the antibiotics, the MICs of the drugs were determined by using a sample of those bacteria.
Detection of carryover elfect. Strain 6/69M was seeded into TSH agar, then aliquots of spleen homogenate were removed from treated mice at 32 and 48 h and poured into 0.1-ml wells bored into the agar, and lastly, the plates were incubated for 48 h at 28°C.
Statistical methods. Using the Student t test, we calculated the geometric mean and the confidence interval of the mean with a 5% risk of error from the data obtained for each group of five mice at each time point. The in vivo growth curves illustrate these results (see Fig. 1 to 3 ). The significance of the difference between the results obtained from control and treated mice was evaluated at each time point. Amoxicillin, streptomycin, and doxycycline were found to have MICs in the ranges published in the most important in vitro study of the 277 strains from Madagascar (25) . For strain 6/69M, aminoglycosides and ofloxacin appeared to be bactericidal at 6 h, and beta-lactams appeared to be bactericidal at 24 h. Only doxycycline was bacteriostatic.
Pharmacokinetics. The early concentrations of each of the seven antibiotics measured in the sera of the mice at 30 min (or 60 min for doxycycline) were of the same order as those found in the sera of humans (14, 18) at approximately the same time following administration of the usual doses ( Table 2 ). The pharmacokinetic characteristics of the drugs in mice infected with Y pestis, especially the short elimination half-lives, were in Fig. 1 (19, 26, 28) . This necessary property was not observed with Y pestis injected subcutaneously either in our preliminary work (data not shown) or in another previously reported study (33) . The experimental model described here, which mimicked the pathogenesis of septicemic plague in humans, enabled us to estimate antibiotic activities against the clinical form of the disease with the worst prognosis.
Despite the brief half-lives of the tested antibiotics in mice, the results of the therapeutic scheme could be analyzed; in the first series of experiments, a single injection provided discriminating results on the bactericidal effects of the antibiotics in a confined model; in the second series, repeated doses given over 48 h enabled us to extrapolate the results more easily to humans.
Although treatments are intended to ensure the survival of animals, the aim of the present study was to compare bacterial counts and not mortality rates. Indeed, the treatment failures could have been due to the short treatment times used in the present study (48 h vis-a-vis 10 days in humans). Then, the in vivo bactericidal effect is more informative about the potencies and rapid activities of the drugs. Anyway, we observed that the mortality rates were in agreement with the bacterial counts.
Up to now, penicillins were considered ineffective in the treatment of human plague (3). Experimental infections and clinical reports have demonstrated the inefficacy of benzylpenicillin (24) , but the dosage used was very low by contemporary standards (400,000 units daily [14a] ). Moreover, benzylpenicillin is primarily active against gram-positive bacteria, and no other beta-lactam antibiotic has been repudiated in a published report. On the other hand, Butler (6) clearly established the effectiveness of ampicillin in a murine model of plague. Moreover, a case of human meningeal plague was successfully treated with ampicillin (5). The results obtained in the present study with amoxicillin, ceftriaxone, and cefotaxime showed that their efficacies were outstanding. Further investigations on beta-lactam antibiotics could well be carried out to confirm or not confirm their efficacies against Y pestis. Indeed, these drugs could be of use in certain clinical situations, such as against septicemic syndrome in an endemic zone and meningitis and in pregnant patients.
Gentamicin used more often than streptomycin, and doxycycline, a lipophilic cycline with an excellent half-life (20 h) and (30, 31) . Its rapid bactericidal effect in vivo confirms its previous successes against murine septicemia caused by Y enterocolitica (28) and Y pseudotuberculosis (19) and confirms the clinical results for Y enterocolitica septicemia (11, 15 
